Loading stock data…
CDNA
$22.75+0.80 (+3.64%)
After Hours$22.23-0.52 (-2.27%)· Last close Jun 9
CareDx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CareDx, Inc. in the Healthcare sector is trading at $22.75. Wall Street consensus targets $25.80 (5 analysts), implying a +13.4% move over the next 12 months. The stock is currently near its 52-week high of $24.02, remaining 26.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +13.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$22.75
Potential Downside
0%
Whystock Fair Value$22.75
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$25.80+13.4%
Range$21.00 – $28.00
Fundamentals
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney tra...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.61%
Volume
Today's trading volume
724,460
Recent News
CareDx (CDNA) Valuation Check After Choppy Trading And Growing AI Diagnostics Story
CareDx at a glance CareDx (CDNA) has drawn investor attention after a period of mixed recent returns, with the stock roughly flat over the past month but higher over the past 3 months and the past year. See our latest analysis for CareDx. Recent trading has been choppy, with the share price down 3.7% over the past week but ahead over the past quarter and year to date. This suggests momentum has been improving after earlier weakness. If you are looking beyond CareDx and want to see what else...
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv
A Look At CareDx (CDNA) Valuation After Recent Share Price Momentum Cools
Understanding CareDx’s recent share performance CareDx (CDNA) has drawn renewed attention after recent price moves, with the stock showing a return of 14.47% over the past month and 1.60% over the past 3 months, prompting closer scrutiny from investors. See our latest analysis for CareDx. Set against a 1 year total shareholder return of 38.17% and a 3 year total shareholder return of about 2.5x, the recent 7 day share price pullback and softer 1 day move suggest momentum has cooled after a...
CareDx, Inc Q1 2026 Earnings Call Summary
Moby summary of CareDx, Inc's Q1 2026 earnings call